Application of the model‐informed drug development paradigm to datopotamab deruxtecan dose selection for late‐stage development
CPT: Pharmacometrics & Systems Pharmacology · 2024-01 · 13 (1) · 23-28
DOI: 10.1002/psp4.13058 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2023-11. Verfasst von Yasong Lu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Quantitative Clinical Pharmacology, Daiichi Sankyo, Inc., Basking Ridge, New Jersey, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antineoplastic Agents, Immunoconjugates. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
To replace the conventional maximum tolerated dose (MTD) approach, a paradigm for dose optimization and dose selection that relies on model‐informed drug development (MIDD) approaches has been proposed in oncology. Here, we report our application of an MIDD approach during phase I to inform dose selection for the late‐stage development of datopotamab deruxtecan (Dato‐DXd). Dato‐DXd is a TROP2‐directed antibody‐drug conjugate being developed for advanced/metastatic non‐small cell lung cancer (NSCLC) and other tumors. Data on pharmacokinetics (PKs), efficacy, and safety in NSCLC were collected in the TROPION‐PanTumor01 phase I dose‐expansion and ‐escalation study over a wide dose range of 0.27–10 mg/kg administered every 3 weeks. Population PK and exposure–response analyses were performed iteratively at three data cutoffs to inform dose selection. The 6 mg/kg dose was identified as the optimal dose by the second data cutoff analysis and confirmed by the subsequent third data cutoff analysis. The 6 mg/kg dose was more tolerable (i.e., lower rates of interstitial lung disease, stomatitis, and mucosal inflammation) than the MTD (8 mg/kg) and was more efficacious than 4 mg/kg (simulated mean objective response rate: 23.8% vs. 18.6%; mean hazard ratio of progression‐free survival: 0.74) – a candidate dose studied just below 6 mg/kg. Therefore, the 6 mg/kg dose was judged to afford the optimal benefit–risk balance. This case study demonstrated the utility of an MIDD approach for dose optimization and dose selection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Quantitative Clinical Pharmacology, Daiichi Sankyo, Inc., Basking Ridge, New Jersey, USA.
- Certara Strategic Consulting, Princeton, New Jersey, USA.
- QuanTx Consulting, Mountain View, California, USA.
- Global Oncology R&D, Daiichi Sankyo, Inc., Basking Ridge, New Jersey, USA.
- Global Oncology Clinical Development, Daiichi Sankyo Europe GmbH, Munich, Germany.
ORCID-Profile: Yasong Lu, Kashyap Patel, Hong Zebger-Gong, Pavan Vaddady
Zitieren
APA
Lu, Y., Liang, S., Hong, Y., Tajima, N., Patel, K., Li, H., Wada, D. R., Greenberg, J., Petrich, A., Zebger-Gong, H., Shuster, D., & Vaddady, P. (2024). Application of the model‐informed drug development paradigm to datopotamab deruxtecan dose selection for late‐stage development. CPT: Pharmacometrics & Systems Pharmacology, 13(1), 23-28. https://doi.org/10.1002/psp4.13058
Vancouver
Lu Y, Liang S, Hong Y, Tajima N, Patel K, Li H, et al. Application of the model‐informed drug development paradigm to datopotamab deruxtecan dose selection for late‐stage development. CPT: Pharmacometrics & Systems Pharmacology. 2024;13(1):23-28. doi:10.1002/psp4.13058
BibTeX
@article{Lu2024,
author = {Lu, Yasong and Liang, Shuang and Hong, Ying and Tajima, Naoyuki and Patel, Kashyap and Li, Hanbin and Wada, David R and Greenberg, Jon and Petrich, Adam and Zebger-Gong, Hong and Shuster, Dale and Vaddady, Pavan},
title = {Application of the model‐informed drug development paradigm to datopotamab deruxtecan dose selection for late‐stage development},
journal = {CPT: Pharmacometrics & Systems Pharmacology},
year = {2024},
volume = {13},
number = {1},
pages = {23--28},
doi = {10.1002/psp4.13058}
}
EUVIMED